The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Not too shabby results on an Ipi Study

Forums General Melanoma Community Not too shabby results on an Ipi Study

  • Post
    Linny
    Participant

      Past President of ECCO, Professor Alexander Eggermont, Directeur Général of the Institut Gustave Roussy Comprehensive Cancer Center (France), who specialises in the treatment of melanoma, commented: "This pooled analysis clearly demonstrates that ipilimumab can lead to long-lasting tumour control in metastatic melanoma patients. With a response rate of only 10-15%, one can achieve more than 3-10 years survival in 17-25% of patients who have received only a few doses of ipilimumab. Thus, patients apparently can keep residual tumours under control for a long time when the immune system is properly 'reset', and the concept of 'clinical cures' becomes a reality. These survival results could even double or triple with anti-PD1/PDL1 monoclonal antibodies, and metastatic melanoma could become a curable disease for perhaps more than 50% of patients over the coming 5-10 years."

      http://esciencenews.com/articles/2013/09/27/longest.follow.melanoma.patients.treated.with.ipilimumab.shows.some.survive.10.years

      Considering where we were with Melanoma even as recently as 2010, this is pretty astounding.

      I just with there was a way to "fast forward" Anti-PD1/PDL1 and get it on the market.

    Viewing 2 reply threads
    • Replies
        Roxy1453
        Participant
          I could be one of the lucky ones responding to IPI:-). My Dr was sure my Mel was back in my lung. I had a biop and it showed it was not Mel! He thinks the IPI taught my body to fight the Mel cells and it was Mel but now is gone!
          I go back for another CT Oct 11. If the spot has grown this is all out the window and he’s taking it out. So, more wait and see!
          This is all so promising thought.
          Roxy1453
          Participant
            I could be one of the lucky ones responding to IPI:-). My Dr was sure my Mel was back in my lung. I had a biop and it showed it was not Mel! He thinks the IPI taught my body to fight the Mel cells and it was Mel but now is gone!
            I go back for another CT Oct 11. If the spot has grown this is all out the window and he’s taking it out. So, more wait and see!
            This is all so promising thought.
            Roxy1453
            Participant
              I could be one of the lucky ones responding to IPI:-). My Dr was sure my Mel was back in my lung. I had a biop and it showed it was not Mel! He thinks the IPI taught my body to fight the Mel cells and it was Mel but now is gone!
              I go back for another CT Oct 11. If the spot has grown this is all out the window and he’s taking it out. So, more wait and see!
              This is all so promising thought.
          Viewing 2 reply threads
          • You must be logged in to reply to this topic.
          About the MRF Patient Forum

          The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

          The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

          Popular Topics